Medical Cannabis and Speech-Blocking Tics: Case Reports

Medical cannabis case studies · Literature checked 2 October 2026

A person with Tourette syndrome may find a tic interrupts speech so severely that ordinary conversation becomes difficult. A 2017 report described marked improvement in two such patients during medical cannabinoid treatment. The unusual feature was the type of disability being addressed: the ability to get words out. [1]

Evidence at a glance: two specialist-treated cases, followed by a broader and mixed clinical-trial literature. Improvement in speech-blocking tics does not establish a treatment for developmental stuttering.

Two-dimensional structural formula of delta-9-tetrahydrocannabinol, also called THC. — Chemical structure of THC. The case reports involved THC-containing medicines; this is not evidence for CBD alone. Harbin, via Wikimedia Commons. Public-domain chemical structure.

The two clinical cases

Jakubovski and Müller-Vahl described a 19-year-old and a 16-year-old with severe vocal blocking and repeated speech, or palilalia. Their difficulties had initially been treated as stuttering. Specialist reassessment identified complex vocal tics. The older patient received authorised vaporised medical cannabis; the younger initially received prescribed dronabinol. Both improved. At eight months, the older patient conversed fluently with clinicians and described near-fluent speech in most situations. He reported feeling high early in treatment, an effect that later subsided. These were clinical treatments with identified medicines, rather than observations of illicit use. [1]

Why the diagnosis changes the interpretation

A description such as “cannabis restored speech” omits the most important qualifier: what had been preventing speech in the first place? Two conditions can sound similar to a listener while needing different assessment and treatment. It would be an unjustified leap to turn these observations into a claim that cannabis treats all stuttering, all speech difficulties or Tourette syndrome in every patient.

The distinction also changes what a meaningful outcome looks like. A general reduction in tic counts may not adequately describe whether someone can answer a question in class, participate in conversation or use the telephone. Research focused on this particular symptom would ideally measure communication and participation as well as overall tic severity.

What later controlled trials found

The 2023 CANNA-TICS trial enrolled 97 adults with Tourette syndrome or another chronic tic disorder. Participants received nabiximols or placebo. The predefined responder threshold was at least a 25% reduction in a standard tic score after 13 weeks. It was reached by 14 of 64 participants receiving nabiximols and 3 of 33 receiving placebo, but the trial did not formally demonstrate superiority on its primary endpoint. Exploratory improvements should therefore be interpreted cautiously. [2]

Another 2023 trial used an oral THC–CBD oil in 22 adults with severe Tourette syndrome, with each participant receiving active treatment and placebo in separate periods. Tic scores improved more during active treatment. However, eight participants reported cognitive difficulties such as slower thinking, memory lapses or poor concentration. The study was small and short, and many participants correctly guessed which treatment they had received. [3]

A 2025 adolescent pilot randomised ten participants, with seven completing the full protocol. Its principal purpose was to test the feasibility of a larger study. Two participants discontinued because of adverse events, one during active treatment and one during placebo. Its small size cannot establish long-term safety or routine effectiveness in young people. [4]

How to read the apparent disagreement

The studies do not all ask the same question. An unusual case involving a specific disabling tic is different from a trial measuring average change across a broader group. Products, routes, study duration and outcome definitions also differ. A favourable observation and an inconclusive primary trial result can coexist without either being dismissed.

For a treatment decision, the useful issue is the balance between functioning gained and functioning lost. Easier speech would be a substantial benefit, but reduced concentration could still matter at school or work. Recording both prevents an impressive improvement in one symptom from becoming a claim that every aspect of health improved.

What these reports justify

They justify further investigation of a clearly defined clinical problem. They do not provide a basis for choosing a commercial strain by name or recreating a published regimen. In particular, the presence of a teenager in a case report is not a safety endorsement for treating children.

A specialist discussion can identify the target symptom, review previous treatment and set practical goals. If an individual treatment trial is undertaken within appropriate clinical care, its review should include communication, daily participation, cognition and adverse effects. The strongest future evidence would come from larger controlled studies that report those outcomes transparently, including patients who stop treatment.

This article explains published clinical evidence. Individual cases cannot predict personal treatment response. Decisions about prescription medicines belong with the treating clinician.